视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比

doi:10. 13281/j. cnki. issn.1004-4469. 2020. 01. 012

眼科

视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比

周瑞陈娟林思勇

中南大学爱尔眼科学院天津爱尔眼科医院，天津300020

收稿日期:2019-02-18 出版日期:2020-01-25 发布日期:2020-02-12
通讯作者: 林思勇，Email：siyonglin@163.com

Comparison of different treatment regimens of macular edema secondary to branch retinal vein occlusion with intravitreal injection of ranibizumab

Zhou Rui, Chen Juan, Lin Siyong

Aier School of Ophthalmology, Central South University; Tianjin Aier Eye Hospital, Tianjin, 300020, China

Received:2019-02-18 Online:2020-01-25 Published:2020-02-12
Contact: Lin Siyong, Email: siyonglin@163.com

摘要/Abstract

摘要： 目的比较视网膜分支静脉阻塞继发黄斑水肿（macular edema secondary to branch retinal vein occlusion，BRVO-ME）玻璃体注射雷珠单抗（intravitreal injection of ranibizumab, IVR）1+PRN与3+PRN方案的疗效及安全性。设计回顾性病例系列。研究对象 2016年1月至2018年3月天津爱尔眼科医院接受IVR的70例BRVO-ME患者。方法患者分为两组，注射1次后按需治疗者为1+PRN组；每月1次连续注射3个月后按需治疗者为3+PRN组。观察两组治疗前后最佳矫正视力（BCVA）、中央视网膜厚度（central retinal thickness, CRT）、中央脉络膜厚度（central choroid thickness，CCT）变化及并发症情况。主要指标 BCVA、CRT、CCT。结果观察12个月时，1+PRN组BCVA较基线提高了（0.42±0.42）（P＜0.05），CRT较基线降低了（385.96±344.23）μm （P＜0.05），CCT较基线降低了（13.03±54.46）μm （P＞0.05）。3+PRN组BCVA较基线提高了（0.43±0.39）（P＜0.05），CRT较基线降低了（524.74±339.20）μm （P＜0.05），CCT较基线降低了（5.00±28.04）μm （P＞0.05）。两组间BCVA、CRT、CCT变化无统计学差异（P均＞0.05）。观察期内1+PRN组平均IVR注射（3.50± 0.99）次，3+PRN组（4.25±0.73）次（P＜0.05）。结论 IVR 1+PRN及3+PRN两种方案对BRVO-ME短期疗效显著，安全性较好；两种治疗方案对于短期内提高BCVA、减轻ME疗效相似，但1+PRN组需要注射的次数低于3+PRN组。BRVO-ME患者两种方案治疗前后CCT无明显变化。（眼科， 2020, 29： 63-67）

关键词: , 视网膜分支静脉阻塞；黄斑水肿；雷珠单抗

Abstract: Objective To compare the clinical efficacy and safety of IVR regimens of 1+PRN and 3+PRN for macular edema secondary to branch retinal vein occlusion (BRVO-ME). Design Retrospective case series. Participants 70 cases of BRVO-ME received intravitreal injection of ranibizumab from January 2016 to March 2018 in Tianjin Aier Eye Hospital. Methods All patients were divided into 1+PRN group and 3+PRN group according to the treatment regimen. Patients receiving PRN after one injection were classified to 1+PRN group, and patients receiving PRN after three months of continuous injection were classified to 3+PRN group. The mean LogMAR BCVA, central retinal thickness (CRT) and central choroid thickness (CCT) of the two groups of patients as well as complications during the follow-up were observed. Main Outcome Measures BCVA, CRT, CCT. Results At the end point of observation (12 months), BCVA increased by 0.42±0.42 (P<0.05), CRT decreased by (385.96±344.23) μm (P＜0.05), CCT decreased by (13.03±54.46) μm (P>0.05) compared with the baseline in the 1+PRN group. BCVA increased by 0.43±0.39 (P＜0.05), CRT decreased by (524.74±339.20) μm (P＜0.05), CCT decreased (5.00±28.04) μm (P>0.05) compared with the baseline in the 3+PRN group. There was no significant difference between the two groups in variation of BCVA, CRT and CCT (all P>0.05). During the observation period, the average IVR injection times of the 1+PRN group were (3.50±0.99) times, and the IVR times of the 3+PRN group were (4.25±0.73) times (P＜0.05). Conclusions Both IVR treatment regimen of 1+PRN and 3+PRN have significant short-term efficacy and good safety for BRVO-ME. The 1+PRN group achieved similar visual outcomes，reducing CRT and reducing macular edema for BRVO-ME with fewer injections compared with the 3+PRN group. Both treatments had no significant effect on the CCT of BRVO-ME patients before and after treatment. (Ophthalmol CHN, 2020, 29: 63-67)

Key words: branch retinal vein occlusion, macular edema, ranibizumab

周瑞陈娟林思勇. 视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比[J]. 眼科, doi: 10. 13281/j. cnki. issn.1004-4469. 2020. 01. 012.

Zhou Rui, Chen Juan, Lin Siyong. Comparison of different treatment regimens of macular edema secondary to branch retinal vein occlusion with intravitreal injection of ranibizumab[J]. Ophthalmology in China, doi: 10. 13281/j. cnki. issn.1004-4469. 2020. 01. 012.

[1]	李建军张莉彭晓燕. 远程眼科眼底像阅片诊断应注意的问题[J]. 眼科, 2104, 23(4): 217-220.
[2]	董贺徐少凯张繁友. Nd∶YAG激光击射瞳孔膜治疗瞳孔膜闭继发青光眼的临床观察[J]. 眼科, 2104, 23(4): 260-263.
[3]	张潇王忠海李莹姜洋罗岩陈秉钧丁欣. 玻璃酸钠及碱性成纤维细胞生长因子滴眼液用于单纯干眼和LASIK术后患者的临床疗效[J]. 眼科, 2104, 23(4): 274-279.
[4]	袁昱王晶晶. 抗VEGF与激光治疗非缺血性视网膜分支静脉阻塞继发黄斑水肿的临床对比研究[J]. 眼科, 2020, 29(3): 209-213.
[5]	王怀洲1 胡曼2 辛晨1 石砚1 李猛1 王宁利1. 微导管辅助的小梁切开术治疗原发性先天性青光眼的远期疗效观察[J]. 眼科, 2020, 29(1): 15-19.
[6]	王婧张楠余烁刘新丽卢弘. 内毒素耐受对内毒素诱导的葡萄膜炎炎症程度及虹膜睫状体中PI3K/AKT 信号通路的影响[J]. 眼科, 2020, 29(1): 50-54.
[7]	朱谷雨张景尚万修华. 炎性因子在乙肝病毒携带的白内障患者房水中的表达及意义[J]. 眼科, 2020, 29(1): 69-72.
[8]	陈宁1 梁娜2 黄帅2 郭立坤2 马海鹏2 李钰泓2. 逆行置入新型RS硅胶管在下泪小管断裂吻合术中的应用[J]. 眼科, 2020, 29(1): 73-74.
[9]	冯丙岂刘旭阳何芬李丹丽张达人赵林樊宁. 两个成骨不全家系的COL1A1基因突变筛查及临床特征分析[J]. 眼科, 2019, 28(4): 273-279.
[10]	赵琦杨文利李栋军王子杨陈伟李逸丰崔蕊沈琳鲜军舫. IOLMaster700与IOLMaster500眼轴测量的一致性评价[J]. 眼科, 2019, 28(3): 235-238.
[11]	辛晨石砚王怀洲王宁利. 以光纤微导管为工具的青光眼微创手术[J]. 眼科, 2019, 28(2): 85-87.
[12]	于周兴李绍伟霍冬梅徐漫石帅刘畅赵瑞华 . 光线追踪法测算角膜屈光术后人工晶状体度数准确性评估[J]. 眼科, 2019, 28(2): 98-103.
[13]	刘月明延艳妮李洋魏文斌. 国产敷贴器治疗合并严重渗出性视网膜脱离的Sturge-Weber综合征的临床观察[J]. 眼科, 2019, 28(2): 125-128.
[14]	肖明马代金. 联合应用Corvis ST和Pentacam角膜地形图诊断圆锥角膜[J]. 眼科, 2019, 28(2): 150-154.
[15]	秦健翔解彦茜胡城王小洁梁远波. 针刺分离联合巩膜通道重建术治疗青光眼术后远期失败滤过泡[J]. 眼科, 2019, 28(1): 39-42.

视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比

Comparison of different treatment regimens of macular edema secondary to branch retinal vein occlusion with intravitreal injection of ranibizumab

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价